Respiratory Inhaler Devices Global Market Report 2024

The global respiratory inhaler devices market has grown strongly in recent years. It will grow from $38.54 billion in 2023 to $41.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to smoking epidemic, allergic disorders, pharmaceutical innovation, aging population.

The global respiratory inhaler devices market is expected to see strong growth in the next few years. It will grow to $54.72 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to air quality concerns, digital health integration, regulatory emphasis on inhaler safety, personalized treatment. Major trends in the forecast period include inhaler device miniaturization, sustainability and eco-friendly inhalers, home-based care, technological advancements.

The prevalence of respiratory diseases is on the rise, and this phenomenon is poised to steer the growth of the respiratory inhaler devices market. Respiratory diseases encompass a spectrum of disorders that affect the lungs and the respiratory system, often resulting in breathing difficulties and compromised lung function. These conditions include ailments like asthma, chronic obstructive pulmonary disease (COPD), respiratory syncytial virus infection, and various other respiratory disorders. The utilization of respiratory inhaler devices is essential in delivering medications directly to the lungs, providing swift and precise relief for individuals battling respiratory illnesses. As an example, recent data from the Centers for Disease Control and Prevention, a prominent US-based public health organization, revealed an increase in tuberculosis (TB) cases reported in the United States, reaching 8,300 cases in 2022, up from 7,874 cases in 2021. This data underscores the significant impetus resulting from the growing prevalence of respiratory diseases, which propels the expansion of the respiratory inhaler devices market.

The burgeoning rates of smoking are anticipated to be a key driver in the growth of the respiratory inhaler devices market. Smoking entails the inhalation and exhalation of vapors generated from the combustion of plant substances, with tobacco being the most common source. Smoking has the potential to inflict substantial damage to the airways and the tiny lung air sacs, known as alveoli, potentially leading to the development of lung diseases such as asthma, COPD, and bronchitis. In this context, respiratory inhaler devices serve as indispensable tools in mitigating and preventing respiratory distress caused by smoking-related issues. Remarkably, the Centers for Disease Control and Prevention reported that nearly 11.5% of adults in the United States, representing an estimated 28.3 million individuals, were smokers in 2021. Consequently, more than 16 million Americans grapple with ailments stemming from smoking. Hence, the upsurge in smoking rates is a potent force propelling the respiratory inhaler devices market.

The primary obstacle facing the respiratory inhaler devices market during the projected period is the lack of patient adherence to prescribed medications. Non-adherence to prescribed treatments can lead to suboptimal inhalation therapy outcomes and a subsequent increase in healthcare costs. This issue encompasses patients who may not adhere to their prescribed medication regimens, a behavior that is notably prevalent among individuals managing chronic conditions with substantial health implications. Illustratively, data from April 2022, sourced from the American Journal of Managed Care, revealed that approximately 50% of individuals failed to follow the prescribed treatment plan for their chronic, long-term medications. Poor adherence contributes to over $500 billion in avoidable healthcare expenditures annually, potentially preventable fatalities numbering over 125,000, and up to 25% of hospitalizations in the United States. Consequently, the lack of patient adherence to prescribed medications serves as a significant constraint in the growth of the respiratory inhaler devices market.

Prominent companies within the respiratory inhaler devices market are increasingly adopting advanced technologies, such as metered dosage inhalers (MDIs), to fortify their market standing. MDIs represent portable aerosol devices designed to deliver precise medication doses to the lungs in the form of an inhaled mist or spray. For instance, a noteworthy development occurred in February 2022, when AptarGroup Inc., a US-based manufacturer specializing in consumer dispensing packaging and drug delivery devices, introduced HeroTracker Sense. This innovative digital respiratory health solution effectively transforms conventional metered dosage inhalers (pMDIs) into intelligent and connected medical devices. HeroTracker Sense aims to monitor the utilization of MDIs by patients, promoting better adherence to prescribed therapies and ultimately enhancing the lives of individuals worldwide grappling with chronic respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory complications triggered by COVID-19. HeroTracker Sense further offers invaluable analytics and insights related to patient training, onboarding, and performance, serving healthcare providers (HCPs) through the Aptar Pharma Cohero Health BreatheSmart Connect portal.

In August 2022, AptarGroup Inc., a US-based manufacturer specializing in consumer dispensing packaging and drug delivery devices, secured the global rights to the Orbital inhaler through an acquisition from Pharmaxis Ltd. This strategic acquisition of the Orbital inhaler rights aligns with Aptar Pharma's mission to expand its respiratory device portfolio and provide innovative solutions catering to patients grappling with respiratory conditions. Pharmaxis Ltd., an Australian-based pharmaceutical company with a clinical-stage focus, developed the groundbreaking Orbital dry powder inhaler. This strategic acquisition demonstrates a commitment to advancing respiratory care.

Major players in the respiratory inhaler devices market are Merck & Co. Inc., Novartis AG, AstraZeneca PLC, Gerresheimer AG, GlaxoSmithKline PLC, 3M, Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., Perrigo Company PLC, AptarGroup Inc., Recipharm AB, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Orion Corporation, Sumitomo Pharma America Inc., Beximco Pharmaceuticals Ltd., Hovione Limited, Vectura Group Limited, H&T Presspart Manufacturing Ltd., Pari Medical Holding GmbH, OMRON Healthcare Europe B.V., Medisol Lifescience Pvt. Ltd., Consort Medical plc.

North America was the largest region in the respiratory inhaler devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory inhaler devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory inhaler devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of respiratory inhaler device products include dry powder inhalers, metered dose inhalers, and nebulizers. Dry powder inhalers (DPIs) are medical devices that dispense powdered medications directly to the lungs for the treatment of respiratory conditions. These inhaler devices encompass both manually operated and digitally operated options. They are commonly used in the management of conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other respiratory issues. Respiratory inhaler devices find application in various healthcare settings, including hospitals, clinics, respiratory care centers, and other medical facilities. They serve as important tools for the delivery of respiratory medications and the management of respiratory conditions.

This report provides respiratory inhaler devices market statistics, including respiratory inhaler devices industry global market size, regional shares, competitors with a respiratory inhaler devices market share, detailed respiratory inhaler devices market segments, market trends and opportunities and any further data you may need to thrive in the respiratory inhaler devices industry. This respiratory inhaler devices market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The respiratory inhaler devices market consists of revenues earned by entities by providing services such as the management of chronic lung diseases and minimizing systemic effects of the drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory inhaler devices market also includes sales of compressed air nebulizers, ultrasonic nebulizers and mesh nebulizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.